Back to today’s briefing

Story perspectives

GSK and SK Bioscience Report Strong Q4 Revenue Growth

2/17/2025

33 6

Summary

Story summary

GSK celebrated a robust 4% sales boost in Q4 2024, reaching £8.12 billion, fueled by a remarkable 17% growth in Specialty Medicines and a staggering 72% leap in oncology revenue, even as vaccine sales dipped by 12%. Meanwhile, SK Bioscience soared with a 73% revenue increase to KRW 1,568 billion, yet grappled with operational losses amid rising costs and waning COVID-19 vaccine demand.

1 of 1

Story summary

GSK celebrated a robust 4% sales boost in Q4 2024, reaching £8.12 billion, fueled by a remarkable 17% growth in Specialty Medicines and a staggering 72% leap in oncology revenue, even as vaccine sales dipped by 12%. Meanwhile, SK Bioscience soared with a 73% revenue increase to KRW 1,568 billion, yet grappled with operational losses amid rising costs and waning COVID-19 vaccine demand.